The Epidemiology of Adipokines in Barrett's Esophagus
The Epidemiology of Adipokines in Barrett's Esophagus
批准号:
7907531
负责人:
JOEL H RUBENSTEIN
金额:
$15.8万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-09-10 至 2012-08-31
关键词:
AddressAdipocytesAdvisory CommitteesApoptosisBarrett EsophagusBioinformaticsBiological MarkersBloodBlood CirculationBody mass indexCase-Control StudiesDevelopmentDysplasiaEndoscopyEpidemiologyEpithelialEsophagealEsophageal AdenocarcinomaEsophagusFatty acid glycerol estersFutureGastric Cardia AdenocarcinomaGastroesophageal reflux diseaseGoalsHealthIncidenceInflammationIntestinesMalignant NeoplasmsMeasurementMechanicsMediatingMedicalMentorsMetaplasiaMolecular WeightMucous MembraneNational Cancer InstituteObesityPatientsPlasmaProtein IsoformsRefluxResearchResearch PersonnelRiskRisk FactorsScreening procedureSerumSignal PathwaySomatomedinsSymptomsTestingTissuesTranslational ResearchUnited StatesUnited States National Institutes of HealthVisceraladipokinesadiponectinadipsincancer typecareercase controlcohortcostcytokineexperienceghrelinhigh riskinflammatory markerleptin receptormodel developmentmortalitynovelnovel strategiesobesity riskpreventprogramsprospectiveresistinstomach cardiatranslational study
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
The incidence of esophageal adenocarcinoma (EAC) is rising faster than that of any other cancer, and the 5- year mortality of this cancer type is 86%. The long-term career objective of the candidate is to develop novel cost-effective strategies for preventing mortality from EAC. Any such strategy will depend on identifying patients at risk for EAC. Barrett's esophagus (BE) is the accepted precursor of EAC. The immediate career objective is to develop novel strategies of identifying patients at risk for BE for the purpose of screening. Obesity is a risk factor for BE and EAC. Others have proposed that this effect is mediated by a mechanical effect promoting gastroesophageal reflux disease. We believe it is unlikely that the risk is due solely to such a mechanical effect; instead, we propose that visceral adipocytes secrete cytokines (adipokines) that promote BE and EAC. Adiponectin, an adipokine whose serum levels are inversely correlated with obesity, inhibits inflammation and promotes apoptosis; deficiency is associated with a number of epithelial cancers. The high molecular weight (HMW) form of adiponectin may be the metabolically active form. We hypothesize that adiponectin deficiency (and the HMW isoform in particular) is closely associated with BE, and is associated with progression of BE toward EAC. We propose a prospective case-control study to estimate the relation between adiponectin in plasma and BE, controlling for potential confounding factors. In addition to examining a potential mechanism to explain the effect of obesity on BE, we hope to identify in adiponectin deficiency a new biomarker of high risk for development of BE. The proposed translational study addresses priorities identified by the National Cancer institute, including to identify "pathophysiologic consequences of reflux, and its interrelationship with BMI, fat distribution, and other factors in the development of esophageal and gastric cardia adenocarcinomas and their precursors." The candidate's career will be developed through the mentored research experience and through didactic courses in epidemiology and bioinformatics. RELEVANCE: The incidence of esophageal adenocarcinoma is rising faster than that of any other cancer in the U.S. This highly fatal cancer is associated with obesity. This study tests the hypothesis that specific substances secreted from fat tissue are strongly associated with the risk of developing esophageal adenocarcinoma. If so, measurement of these substances may be useful in a screening program.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Early Targets in Progression of Barrett's Esophagus to Esophageal Adenocarcinoma
-
批准号:10613011
-
项目类别:
-
资助金额:$39.5万
-
财政年份:2022
-
负责人:JOEL H RUBENSTEIN
-
依托单位:
Validation and Extension of the Michigan Barretts Esophagus pREdiction Tool (M-BERET)
-
批准号:8819830
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:JOEL H RUBENSTEIN
-
依托单位:
Validation and Extension of the Michigan Barretts Esophagus pREdiction Tool (M-BERET)
-
批准号:9001810
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:JOEL H RUBENSTEIN
-
依托单位:
Validation and Extension of the Michigan Barretts Esophagus pREdiction Tool (M-BERET)
-
批准号:9278084
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:JOEL H RUBENSTEIN
-
依托单位:
Early Targets in Progression of Barrett's Esophagus to Esophageal Adenocarcinoma
-
批准号:10155436
-
项目类别:
-
资助金额:$105.33万
-
财政年份:2011
-
负责人:JOEL H RUBENSTEIN
-
依托单位:
Patient Registry-Virtual Biorepository
-
批准号:10155440
-
项目类别:
-
资助金额:$11.13万
-
财政年份:2011
-
负责人:JOEL H RUBENSTEIN
-
依托单位:
Metabolome Risk Factors for Barrett's Esophagus
-
批准号:8118930
-
项目类别:
-
资助金额:$7.7万
-
财政年份:2010
-
负责人:JOEL H RUBENSTEIN
-
依托单位:
Metabolome Risk Factors for Barrett's Esophagus
-
批准号:7978686
-
项目类别:
-
资助金额:$7.73万
-
财政年份:2010
-
负责人:JOEL H RUBENSTEIN
-
依托单位:
The Epidemiology of Adipokines in Barrett's Esophagus
-
批准号:7677289
-
项目类别:
-
资助金额:$15.85万
-
财政年份:2007
-
负责人:JOEL H RUBENSTEIN
-
依托单位:
The Epidemiology of Adipokines in Barrett's Esophagus
-
批准号:7492658
-
项目类别:
-
资助金额:$16.0万
-
财政年份:2007
-
负责人:JOEL H RUBENSTEIN
-
依托单位:
The Epidemiology of Adipokines in Barrett's Esophagus
-
批准号:8132798
-
项目类别:
-
资助金额:$13.62万
-
财政年份:2007
-
负责人:JOEL H RUBENSTEIN
-
依托单位:
The Epidemiology of Adipokines in Barrett's Esophagus
-
批准号:7809419
-
项目类别:
-
资助金额:$0.11万
-
财政年份:2007
-
负责人:JOEL H RUBENSTEIN
-
依托单位:
Esophageal Sensation in Patients with Heartburn
-
批准号:7039846
-
项目类别:
-
资助金额:$1.02万
-
财政年份:2004
-
负责人:JOEL H RUBENSTEIN
-
依托单位:
Patient Registry-Virtual Biorepository
-
批准号:9277835
-
项目类别:
-
资助金额:$11.85万
-
财政年份:--
-
负责人:JOEL H RUBENSTEIN
-
依托单位:
国内基金
海外基金
支链氨基酸代谢紊乱调控“Adipocytes - Macrophages Crosstalk”诱发2型糖尿病脂肪组织功能和结构障碍的作用及机制
-
批准号:81970721
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:陶凌
-
依托单位: